Efficacy, toxicity and nursing of paclitaxel combined with cisplatin in the treatment of recurrent cervical cancer / 国际生物医学工程杂志

Objective:To explore and evaluate the effect of clinical toxicity nursing on the therapeutic effect of paclitaxel combined with cisplatin in the treatment of recurrent cervical cancer.Methods:Sixty patients with recurrent cervical cancer treated in the Second Hospital of Tianjin Medical University from May 2017 to May 2019 were randomly divided into two groups. The control group was given paclitaxel chemotherapy and routine nursing, and the study group was given paclitaxel combined with cisplatin and clinical toxicity nursing.Results:In the study group, the total effective rate of 93.3% was significantly higher than that of 73.3% in the control group ( P<0.05), and the levels of inflammatory indexes, including C-reactive protein (CRP), interleukin-6 (IL-6), white blood cell (WBC) and erythrocyte sedimentation rate (ESR) in the study group were lower than those in the control group ( P<0.05). The incidence of toxicity in the study group was 10.0% lower than that in the control group(36.7%, P<0.05). Conclusions:The use of paclitaxel combined with cisplatin chemotherapy for recurrent cervical cancer and clinical toxic reaction nursing can improve the effectiveness rate of treatment, reduce the levels of various inflammatory indicators, and reduce the incidence of toxic reactions with high safety, thus prolonging the survival time of patients, making it worthy of clinical application.

Dosimetric study of 125I seed implantation by 3D-printing coplanar template for pelvic wall recurrent cervical cancer after radiotherapy / 中华放射医学与防护杂志

Objective To investigate the feasibility of 3D-printing coplanar coordinate template (3D-PCT) for guiding 125I radioactive seed implantation in the treatment of pelvic wall recurrence of cervical cancer on ensuring the accuracy of dose.Methods From Oct 2016 to Dec 2017 in Peking University Third Hospital,totally 10 patients with pelvic wall recurrent cervical cancer after radiotherapy were treated with 125I radioactive seed implantation assisted by 3D-PCT.The median age was 53.5 years old (37-71 years old).KPS score of the cohort were more than 70.All patients had received pelvic radiation therapy previously.The median volume of the lesion was 31.9 cm3 (3.5-58.0 cm3).The prescription dose was 120-180 Gy.The activity of seeds was 0.55-0.67 mCi(1 Ci =3.7 × 1010Bq),while the number of seeds was 12-81 (median 50) on preoperative plan.Radioactive seeds implantation was performed under 3D-PCT guidance according to the preoperative plan.The actual number of implanted seeds was 53 (10-82).Dosimetry parameters of preoperative plan and postoperative plan including D90,D100,V100,V150,V200,external index (EI),conformal index (CI),heterogeneity index (HI),and organat-risk doses of D2 cm3,D1 cm3 and D0.1 cm3 were compared using the nonparametric test.Results The seed number of postoperative plan was more than that of preoperative plan (Z =-2.255,P ＜ 0.05),but all of the dosimetric parameters showed no significant difference (P ＞ 0.05).D2 cm3 and D1 cm3 of rectum for postoperative plan were lower than that of preoperative plan (Z =-2.100,-2.240,P ＜ 0.05),while other dose parameters of normal tisssues showed no statistically significant difference (P ＞ 0.05).Conclusions Assisted by 3D-PCT for 125I radioactive seed implantation in pelvic wall recurrence of cervical cancer,the actual postoperative dose could meet the requirement of the preoperatie plan through the intraoperative optimization of dose.3D-PCT could ensure the precise of delivered dose of 125I radioactive seed implantation.

The clinical application of 3D-printed minimally-invasiveguided template in the inter-stitial brachytherapy treatment of postoperative recurrent cervical cancer / 中国肿瘤临床

Objective: To investigate the application of 3D-printed minimally-invasiveguided template in the treatment of recurrent cer-vical cancer after surgery, assisting interstitial brachytherapy. Methods: From July 2017 to April 2018, a total of 10 patients admitted to Cangzhou Hospital of Integrated Traditional Chinese and Western Medicine in Hebei province with recurrent cervical cancer after radi-cal surgery underwent the 3D-printed customized template-assisted interstitial brachytherapy. According to the specific conditions of patients, different vaginal localization templates were selected for CT simulation localization. The main guidance needle space distribu-tion was designed, and 3D minimally-invasive guidance templates were printed. Then, needles were inserted according to the main guide channel of the template commissioned by medical photosensitive resin. The high-risk clinical target volume (HR-CTV) of 6 Gy/fraction was administered (4 to 6 fractions). Results: Overall, 10 patients were treated with implantation for a total of 52 times. Treat-ment with average scanning CT number for each brachytherapy was (1.58±0.70) times. The average elapsed time for each brachythera-py implant treatment, from plug implant to inserting planting needle satisfactorily with the location of the tumor, was (10.88±2.94) minutes. The mean number of metal needles used was (5.69±1.91) in each brachytherapy. The mean D90 value for high-risk clinical tar-get volume (HR-CTV) was (6.41±0.29) Gy. The cumulative D2cm3 values for the bladder, rectum, and sigmoid colon were (4.75±0.37) Gy, (3.93±0.26) Gy, and (4.33±0.24) Gy, respectively. After 3 months of treatment, the efficacy was evaluated in 8 cases with CR and 2 cas-es with PR. Conclusions: The technology of 3D-printed minimally-invasive guided template shows the advantage of accurate location and superior repeatability in the application of interstitial brachytherapy in treating recurrent cervical cancer after operation, which in-volves less time and insertion needles. The patients had minor aches and few complications. The tumor shrank significantly, which indi-cated a bright future of the technology's clinical application.

Beyond angiogenesis blockade: targeted therapy for advanced cervical cancer / 부인종양

The global burden of advanced stage cervical cancer remains significant, particular in resource poor countries where effective screening programs are absent. Unfortunately, a proportion of patients will be diagnosed with advanced stage disease, and may suffer from persistent or recurrent disease despite treatment with combination chemotherapy and radiation. Patients with recurrent disease have a poor salvage rate, with an expected 5-year survival of less than 10%. Recently, significant gains have been made in the antiangiogenic arena; nonetheless the need to develop effective alternate targeted strategies is implicit. As such, a review of molecular targeted therapy in the treatment of this disease is warranted. In an era of biologics, combined therapy with cytotoxic drugs and molecular targeted agents, represents an exciting arena yet to be fully explored.

Utility of serum squamous cell carcinoma antigen levels at the time of recurrent cervical cancer diagnosis in determining the optimal treatment choice / 부인종양

OBJECTIVE: To investigate the utility of serum squamous cell carcinoma antigen (SCC-Ag) levels upon the diagnosis of recurrent cervical cancer for decision making in patient management. METHODS: Clinical records from 167 cervical cancer patients who developed recurrence between April 1996 and September 2010 were reviewed. A Cox proportional hazards regression model was used to investigate the prognostic significance of serum SCC-Ag levels at the time of recurrence. The effects of various salvage treatments on survival outcomes of recurrent cervical cancer were examined with respect to serum SCC-Ag levels. RESULTS: Serum SCC-Ag levels were elevated (>2.0 ng/mL) in 125 patients (75%) when recurrence was diagnosed. These patients exhibited significantly shorter postrecurrence survival than those with normal SCC-Ag levels (log-rank; p=0.033). Multivariate analyses revealed that an elevated serum SCC-Ag level was an independent prognostic factor for poor postrecurrence survival. In patients with SCC-Ag levels or =14.0 ng/mL, salvage treatment with radiotherapy had only a minimal impact on postrecurrence survival. CONCLUSION: The serum SCC-Ag level measured when cervical cancer recurrence is diagnosed can be useful for deciding upon the appropriate salvage treatment.

Analysis of clinical characteristics and prognosis in patients with recurrent cervical cancer / 대한산부인과학회지

OBJECTIVE: The purpose of this study was to analyze the clinical course and prognosis in patients with recurrent cervical cancer. METHODS: Between January 1999 and December 2003, sixty-three patients were diagnosed as recurrent cervical cancer. The data for clinical characteristics and survival were analyzed retrospectively. Survival after recurrence (SAR) according to prognostic factors was evaluated using Kaplan-Meier analysis with log-rank test. Independent prognostic factors were identified by use of Cox regression model. RESULTS: The most common stage and age group of the patients were FIGO stage Ib (38.1%) and age between 40 and 49 (39.7%) respectively. Distant metastases were present in 29 patients (46.0%) and the most common site was para-aortic lymph node. Median disease-free survival before the recurrence of cervical cancer was 19 months (95% CI = 9.5 - 28.5). Median SAR was 24 months (95% CI = 17.4 - 30.6) and 5-year survival rate after recurrence was 20.0%. In univariate analysis of the prognostic factors, age, FIGO stage, primary treatment with surgery and number of recurred site were statistically significant. But, multivariate analysis showed that only FIGO stage and the number of recurrent site had prognostic significance. CONCLUSION: FIGO stage and number of recurrent site may be independent prognostic factors for the survival in patients with recurrent cervical cancer.

Diagnosis and Treatment of Recurrent Cervical Cancer

Despite recent advances in the early detection method and treatment modalities (surgery and/or radiation and/or chemotherapy), cervical cancer is still an important malignant disease in women. Almost half a million new cases occur every year in the world. The management of recurrent cervical cancers depends on primary treatment, the extent of disease, and performance status. Patients who received primary surgical treatment without radiotherapy (RT) may undergo curative RT. However, most recurrences occur in patients with advanced-stage disease already treated by primary RT. For patients who failed primary RT or surgery plus adjuvant RT and had central relapse without pelvic sidewall recurrence, pelvic exenteration may be necessary. For patients who had pelvic sidewall recurrences, pelvic exenteration is usually not an option with curative intent. In such situation, combined operative and radiotherapeutic treatment (CORT), and laterally extended endopelvic resection (LEER), intraoperative radiotherapy (IORT) have been executed with some success. Simple or radical hysterectomy can be considered for patients who had small uterine and/or vaginal recurrences, but the high frequency of associated morbidities such as urinary and bowel tract injury or fistula is the problem. Patients with multiple or distant metastases are destined to receive cisplatin-based palliative chemotherapy. Recently there was a GOG 179 study that had firstly shown a statistically significant improvement on the overall response rate, median progression-free survival, and median survival. Until now, however, the role of chemotherapy has been very limited.

The efficacy of combination of paclitaxel, ifosfamide, and cisplatin for the treatment of recurrent carcinoma of the uterine cervix / 대한산부인과학회잡지

OBJECTIVE: Paclitaxel, ifosfamide, and cisplatin have moderate single-agent activity in patients with metastatic or recurrent cancer of the uterine cervix. We administered a combination of these three agents (TIP) to patients with recurrent cervical carcinoma to evaluate its activity. METHODS: Forty-three patients were treated with ifosfamide (I) 1500 mg/m2 intravenously over 3 hours on Days 1-3, paclitaxel (T) 135 mg/m2 as a 3-hour intravenous infusion and cisplatin (P) 50 mg/m2 intravenously over 30 min on Day 1. The chemotherapy was repeated every 3 weeks. RESULTS: Thirty-five patients received at least three courses of treatment and were evaluable for response. Eighteen patients (51.4%) achieved an objective response, including 5.7% complete and 45.7% partial responses. The median time to progression and overall survival for all patients were 8.0 and 16.0 months, respectively. The site of recurrence relative to prior radiation field and histopathology (squamous vs other pathology) did not affect the response rate and survival. Patients treated with another chemotherapy regimen before the initiation of TIP regimen showed lower response rate (28.6% vs 66.6%, p=0.027) and shorter survival (14 month vs 25 month, p=0.028). Grade 3 or 4 toxicity included granulocytopenia in 13% of patients, anemia in 8%, thrombocytopenia in 5%. CONCLUSION: The TIP regimen is relatively well tolerated and moderately active in patients with recurrent carcinoma of the uterine cervix. Patients more likely to benefit are those who received TIP regimen for the first time after recurrence.

Surgical Management of Recurrent Cervical Cancer

The majority of patients with recurrent cervical cancer are incurable and treatment is based on the type of primary therapy delivered. Only a very small percentage of the patients with recurrent cervical cancer following primary radiotherapy will have central pelvic recurrences that are amenable to surgical resection and curable by pelvic exenteration. These procedures should be undertaken only after the completion of exhaustive attempts to exclude extrapelvic disease.

A Case of Colonic Metastasis of Recurrent Cervical Cancer / 대한산부인과학회잡지

It is estimated that approximately 35% of patients with invasive cervical cancer will have recurrent or persistent disease following therapy. The common metastatic sites of recurrent cervical cancer included the lung, liver and vertebra, however, colon metastases from cervical cancer were extremely rare. Recently we experienced a case of colonic metastasis in a patient with cervical cancer who had been treated with radiation and chemotherapy. We present this case with a brief review of literature.

Reirradiation in Rcurrent Cervical Cancer Following Definite Radiation Therapy / 대한방사선종양학회지

PURPOSE: To evaluate treatment results in terms of local control, complications and survival after reirraidiation in recurrent cervical cancer following definite radiation therapy. MATERIAL AND METHODS: From November 1987 through March 1998, eighteen patients with recurrent cervical cancer following definite radiation therapy were subsequently treated with reirradiation at Keimyung University Dongsan Medical Center. In regard to the initial FIGO stage, one patient was stage Ia, five were stage IIa, three were IIb, two were IIb and two were IVa. The age range was 37 to 79 years old with median age of 57. The time interval from initial definite radiation therapy to recurrence ranged from 6 to 122 months with a median of 58 months. The recurrent sites were the uterine cervix in seven patients, vagina in ten and pelvic lymph node in one. Reirradiation was performed with external radiation and intracavitary radiation in twelve patients, external radiation and implantation in four and external radiation alone in two. The range of external radiation dose was 2,100~5,400 cGy and the range of the total radiation dose was 3,780~8,550 cGy. The follow-up periods ranged from 8 to 20 months with median of 25 following reirradiation. RESULTS: Fourteen of eighteen patients (78%) had local control just after reirradiation. The two year disease free survival (2YDFS) rate was 53.6%. There were statistically significant differences in the 2YDFS according to both recurrent site (2YDFS 28.5% in uterine cervix, 71.4% in vagina, ( p=0.03)) and the total dose (2YDFS 71.8% in >6,000 cGy , 25% in < OR = 6,000 cGy, p=0.007). Seven of ten patients who were followed for more than 20 months remain alive and disease free (7/18, 39%). Patients treated with external radiation and intracavitary radiation had a higher rate of 2YDFS. Seven patients including 4 patients with no local control experienced local failure in the uterus or vagina and two patients died with distant metastasis. Complications included rectal bleeding in 3 patients, bowel obstruction treated with surgery in two, hematuria in one, radiation cystitis in two, soft tissue swelling in two and vaginal necrosis spontaneously healed in one. There was no statistical difference in complications according to the total dose or the time to recurrence from initial radiation. CONCLUSION: In patients with recurrence following definite radiation therapy in the uterine cervical cancer, reirradiation may be effective but requires an effort to reduce radiation induced severe complications.

A Case of Recurrent Cervical Cancer Responded to Paclitaxel and Carboplatin Combination / 대한부인종양콜포스코피학회잡지

We report the case of a patient with a recurrent squamous cell carcinoma of the cervix, FIGO stage IIa, that metastasized to both lung fields 5 years after primary radical hysterectomy and adjuvant pelvic irradiation. The tumor was resistant to UFT-cisplatin regimen. We used a combination of paclitaxel (175mg/m2 intravenous infusion over 3 hours) and carboplatin with a target area under the curve of 4.5 microgram-h/ml and repeated every 3 weeks. The patient well tolerated the chemotherapy with minor neurologic side effect and myelosuppression controlled by granulocyte colony-stimulating factor. The disease went into remission. Thus, the combination of paclitaxel and carboplatin may be a good combination in recurrent or advanced squamous cell carcinoma of the cervix.

The Results of Hyperfractionated Radiation Therapy Combined with Taxol for Paraaortic Node Recurrence in Cervix Cancer / 대한방사선종양학회지

PURPOSE: The aim of this study was to investigate treatment results, toxicity and efficacy of hyperfractionated radiation therapy combined with paclitaxel for paraaortic node recurrence in cervix cancer. MATERIALS AND METHODS: Between September 1997 to March 1999, 12 patients with paraaortic node recurrence in cervix cancer who previously received radical or postoperative radiotherapy were treated with hyperfractionated radiation therapy combined with paclitaxel. Of these, 2 patients who irradiated less than 30 Gy were excluded, 10 patients were eligible for this study. Median age was 5 1 years. Initial FlGO stage was 1 stage IB1, 2 stage IIA, 7 stage IIB. For initial treatment, 7 patients received radical radiotherapy and 3 received postoperative radiotherapy. The paraaortic field encompassed the gross recur rent disease with superior margin at T 12, and inferior margin was between L5 and S 1 with gap for previously pelvic radiation field. The radiation field was initially anterior and posterior opposed field followed by both lateral field. The daily dose was 1.2 Gy, twice daily fractions, and total radiotherapy dose was between 50.4 and 60 Gy(median, 58.8 Gy). Concurrent chemotherapy was done with paclitaxel as a radiosensitizer. Dose range was from 20 mg/m to 30 mg/m (median, 25 mg/m'), and cycle of chemotherapy was from 3 to 6 (median, 4.5 cycle). Follow-up period ranged from 3 to 21 months. RESULTS: Interval between initial diagnosis and paraaortic node recurrence was range from 2 to 63 months (median, 8 months). The 1 year overall survival rate and median survival were 75% and 9.5 months, respectively. The 1 year disease free survival rate and median disease free survival were 30% and 3 7 months, respectively. At 1 month after treatment, 4 (40%) achieved a complete response and 6 (63%) experienced a partial response and all patients showed response above the partial response. There was distant metastasis in 6 patients and pelvic node recurrence in 2 patients after paraaortic node irradialion. There was 2 patients with grade 3 to 4 leukopenia and 8 patients with grade 1 to 2 nausea/ vom ting which was usually tolerable with antiemetic drug. There was no chronic complication in abdomen and pelvis during follow up period. CONCLUSION: Hyperfractionated radiation therapy combined with paclitaxel as a radiosensitizer showed high response rate and few complication rate in paraaortic node recurrence in cervix cancer. Therefore, present results suggest that hyperfractionated radiation therapy combined with paclitaxel chemotherapy can be used as optimal treatment modality in this patients.

SCC-Ag As A Significant Prognostic Indicator in Recurrent Cervical Cancer / 대한산부인과학회잡지

OBJECTIVE: This study was performed to identify the prognostic factor for survival of patients with recurrent cervical cancer. METHODS: Sixty-eight patients were diagnosed as recurrent cervical cancer at the Seoul National University Hospital from January, 1988 to December, 1998. Recurrence was defined as new evidence of tumor after 6 months of disease free survival. Retrospective analysis was done in terms of clinical features and the Cox proportional hazard model was used to identify independent variables associated with an improved survival rate. Histopathologic types were distributed as follows; squamous cell carcinoma in 70.6%, adenocarcinoma in 11.8%, adenosquamous cell carcinoma in 11.8%, and small cell carcinoma in 1.5%. Distribution of FIGO stage was as follows; stage I in 25.0%, stage II in 66.2%, and stage III in 4.4%. Sites of recurrence were as follows; central pelvic recurrence in 44.1%, pelvic side wall recurrence in 11.8%, and distant metastasis in 44.1% and the most common site of distant recurrence was extrapelvic lymph nodes (29.4%). 29.4% of recurrences were observed within the first 12 months after initial therapy, 50.0% within 2 years and 64.7% within 3 years. RESULTS: Positive rate of SCC-Ag at initial diagnosis was 45.2% with cutoff value of 2.0 ng/ml. Positive rate of SCC-Ag at the diagnosis of recurrence was 60.0%. Overall response rate to the treatment was 29.1%. Complete response rate was higher in central pelvic recurrrence than pelvic side wall recurrence and distant metastasis (P = 0.002) and also higher in normal SCC-Ag level (< or = 2.0 ng/ml) at the diagnosis of recurrence than elevated level (P = 0.032). Cumulative survival rates of 1 year after recurrence was 66.8%, 2 year 36.7%, and 5 year 18.7%. Central recurrence showed higher cumulative survival rate than pelvic side wall or distant recurrence (P = 0.029). The patients with elevated SCC-Ag level at the time of diagnosis of recurrence showed lower cumulative survival rate than those with normal SCC-Ag level (P < 0.001). Cox proportional hazard model showed that SCC-Ag elevation at the time of diagnosis of recurrence retained significant values in predicting survival(OR = 2.56; 95% CI = [1.22-5.39]; P = 0.01). CONCLUSION: SCC-Ag elevation at the diagnosis of the recurrence is a strong independent prognostic indicator for survival of patients with recurrent cervical cancer.

Clinical Characteristics of 53 Patients with Recurrent Cervical Cancer Showing Lung Metastasis / 대한산부인과학회잡지

OBJECTIVE: Pulmonary metastasis from carcinoma of the uterine cervix is relatively rare, and their clinical outcomes are not still remain unknown. This study is to evaluate survival and prognostic factors in recurrent cervical cancer patients showing lung metastasis. METHODS: From Jan. 1993 to Dec. 1996, 53 recurrent cervical cancer patients showing lung metastasis, registered in Korea Cancer Center Hospital, were retrospectively evaluated with respect to their clinical characteristics, response rate to salvage therapy, survival and prognostic factors. RESULTS: Median age of patients at recurrence was 58 years, and median interval of initial diagnosis to recurrence was 17 months. The most common histologic type was squamous cell carcinoma(82%), followed by adenocarcinoma(6%), adenosquamous(6%), and others(6%). Response rate to salvage therapy was 47%(complete response rate 23.5%, partial response rate 23.5%), and median survival was 10 months(range 1-39). 3 year survival rate was 18%. Age, initial stage, initial tumor size, interval of recurrence and type of chemotherapeutic regimen were not significant prognostic factors, but squamous cell carcinoma antigen(SCC) level at recurrence and response to salvage therapy was significant(p=0.0087, p=0.0104). CONCLUSION: Survival of recurrent cervical cancer patients with lung metastasis was poor despite salvage therapy. Those patients who showed low SCC level at recurrence and good response to salvage therapy had favorable outcomes.

Prognosis of the Patients Showing Metastasis to the Para-aortic or/and Supraclavicular Lymph Nodes at the Time of Diagnosis of Recurrence of the Cervical Cancer / 대한산부인과학회잡지

This study was performed to evaluate the survival of the patients found to have metastasis only to the para-aortic or/and supraclavicular lymph nodes at the time of diagnosis of recurrence of the cervical cancer. In addition, the survival was compared between the patients metastasis limited to the para aortic or/and supraclavicular lymph nodes only and those having other concurrent metastatic sites. From Jan. 1991 to Dec. 1995, total 105 patients were identified to have metastasis of para-aortic or/and supraclavicular lymph nodes by computerized tomography(CT) scan or/and percutaneous needle aspiration cytology. Their medical records and cytologic slides were reviewed. The information about survival and disease status was obtained from the last follow-up date in medical records or from interview via telephone. Forty-one(39%) patie-nts showed para-aortic node metastasis: 23 patients(22%), supraclavicular node metastasis; 41(39%) patients, para-aortic and supraclavicular lymph node metastasis. Thirty-one(76%) of 41 patients involving para-aortic lymph node metastasis showed recurrent disease limited to the lymph nodes only: Eight(35%) of 23 patients with supraclavicular lymph node metastasis and sixteen(39%) of 41 patients with both lymph nodes metastasis showed lymph node metastasis only. Supraclavicular lymph node metastasis was found concurrently in 41(50%) of 82 patients with para-aortic lymph node metastasis at the time of recurrence. Forty-two patients(40 %) had been found to have previous pelvic lymph node metastasis at the time of initial treatm ent of the cervical cancer. The 3-year survival was 13.9% in patients with para-aortic lymph node metastasis: 0% with supraclavicular lymph node metastasis: 20.3% in para-aortic and supraclavicular lymph node metastasis. In addition, 3-year survival rate was not significantly different among the groups with different lymph node metastasis. Furthermore, there was no difference in the 3-year survival rate between the patients with lymph node metastasis only and those with other concurrent metastatic sites. These results showed that survival of the patients with metastasis to para-aortic or/and supraclavicular lymph nodes only at the time of diagnosis of recurrent cervical cancer may be still poor and was not different compara to that of the patients with other concurrent sites of metastasis.